Nothing Special   »   [go: up one dir, main page]

WO2008010061A3 - 3-azabicyclo [3.1.0] hexane vanilloid receptor ligands, pharmaceutical compositions containing them, and processes for their preparation - Google Patents

3-azabicyclo [3.1.0] hexane vanilloid receptor ligands, pharmaceutical compositions containing them, and processes for their preparation Download PDF

Info

Publication number
WO2008010061A3
WO2008010061A3 PCT/IB2007/002002 IB2007002002W WO2008010061A3 WO 2008010061 A3 WO2008010061 A3 WO 2008010061A3 IB 2007002002 W IB2007002002 W IB 2007002002W WO 2008010061 A3 WO2008010061 A3 WO 2008010061A3
Authority
WO
WIPO (PCT)
Prior art keywords
azabicyclo
processes
hexane
receptor ligands
preparation
Prior art date
Application number
PCT/IB2007/002002
Other languages
French (fr)
Other versions
WO2008010061A2 (en
Inventor
Laxmikant Atmaram Gharat
Neelima Khairatkar Joshi
Jitendra Maganbhai Gajera
Pravin Sabhajit Yadav
Original Assignee
Glenmark Pharmaceuticals Sa
Laxmikant Atmaram Gharat
Neelima Khairatkar Joshi
Jitendra Maganbhai Gajera
Pravin Sabhajit Yadav
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glenmark Pharmaceuticals Sa, Laxmikant Atmaram Gharat, Neelima Khairatkar Joshi, Jitendra Maganbhai Gajera, Pravin Sabhajit Yadav filed Critical Glenmark Pharmaceuticals Sa
Publication of WO2008010061A2 publication Critical patent/WO2008010061A2/en
Publication of WO2008010061A3 publication Critical patent/WO2008010061A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to substituted 3-azabicyclo [3.1.0] hexane derivatives, which are useful as vanilloid receptor ligands, methods of treating diseases, conditions and/or disorders modulated by vanilloid receptors with them, and processes for preparing them.
PCT/IB2007/002002 2006-07-17 2007-07-16 3-azabicyclo [3.1.0] hexane vanilloid receptor ligands, pharmaceutical compositions containing them, and processes for their preparation WO2008010061A2 (en)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
IN1136/MUM/2006 2006-07-17
IN1136MU2006 2006-07-17
US83556006P 2006-08-03 2006-08-03
US60/835,560 2006-08-03
IN381MU2007 2007-02-27
IN381/MUM/2007 2007-02-27
US89367507P 2007-03-08 2007-03-08
US60/893,675 2007-03-08
US94771507P 2007-07-03 2007-07-03
US60/947,715 2007-07-03

Publications (2)

Publication Number Publication Date
WO2008010061A2 WO2008010061A2 (en) 2008-01-24
WO2008010061A3 true WO2008010061A3 (en) 2008-04-17

Family

ID=38928004

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2007/002002 WO2008010061A2 (en) 2006-07-17 2007-07-16 3-azabicyclo [3.1.0] hexane vanilloid receptor ligands, pharmaceutical compositions containing them, and processes for their preparation

Country Status (2)

Country Link
AR (1) AR061905A1 (en)
WO (1) WO2008010061A2 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CL2008002054A1 (en) 2007-07-17 2009-05-29 Hoffmann La Roche Method for the regeneration of a cation exchange chromatography column after elusion of monopeglated erythropoietin and method to obtain a monopeglated erythropoietin, incorporating the regeneration method of the cation exchange column.
CL2008002053A1 (en) 2007-07-17 2009-05-22 Hoffmann La Roche Method for the purification of a monopeglated erythropoietin (epompeg) which consists of providing a solution containing mono, poly and non-peglated erythropoietin and passing it through two steps of cation exchange chromatography and a method to produce epo mpeg that includes a purification method.
EP2025674A1 (en) 2007-08-15 2009-02-18 sanofi-aventis Substituted tetra hydro naphthalines, method for their manufacture and their use as drugs
WO2009034433A2 (en) * 2007-09-10 2009-03-19 Glenmark Pharmaceuticals, S.A. 3-azabicyclo [3.1.0] hexane derivatives as vanilloid receptor ligands
WO2009090548A2 (en) * 2008-01-17 2009-07-23 Glenmark Pharmaceuticals, S.A. 3-azabicyclo [3.1.0] hexane derivatives as vanilloid receptor ligands
BR112013003815A2 (en) * 2010-08-20 2019-09-24 Gruenenthal Chemie substituted cyclic carboxamide derivatives and urea derivatives as vanyloid receptor ligands
US10077238B2 (en) * 2014-06-12 2018-09-18 Allocyte Pharmaceuticals Ag Small molecule LFA-1 inhibitors
EP3976194A2 (en) 2019-05-31 2022-04-06 Ikena Oncology, Inc. Tead inhibitors and uses thereof
AU2020282759A1 (en) * 2019-05-31 2021-12-23 Ikena Oncology, Inc. TEAD inhibitors and uses thereof
KR20220087497A (en) 2019-10-18 2022-06-24 더 리전츠 오브 더 유니버시티 오브 캘리포니아 Compounds and methods for targeting pathogenic blood vessels
RU2755206C1 (en) 2020-05-20 2021-09-14 Федеральное государственное бюджетное учреждение науки Тихоокеанский институт биоорганической химии им. Г.Б. Елякова Дальневосточного отделения Российской академии наук (ТИБОХ ДВО РАН) Agent with prolonged analgesic action and medicinal product based thereon

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993018001A1 (en) * 1992-03-02 1993-09-16 Pfizer Inc. Preparation of intermediates in the synthesis of quinoline antibiotics
US5475116A (en) * 1994-04-29 1995-12-12 Pfizer Inc. Aza bicyclo[3,1,0]hexane intermediates useful in the synthesis of quinolones
US6184380B1 (en) * 1999-01-25 2001-02-06 Pfizer Inc. Process for preparing naphthyridones and intermediates
US6194438B1 (en) * 1998-12-02 2001-02-27 Pfizer Inc. Derivatives of 2-(2-oxo-ethylidene)-imidazolidin-4-one, and compositions and methods for inhibiting abnormal cell growth comprising said derivatives
WO2002090326A1 (en) * 2001-05-02 2002-11-14 Smithkline Beecham P.L.C. Heterocyclic ureas, their preparation and their use as vanilloid receptor antagonists
WO2004052857A1 (en) * 2002-12-10 2004-06-24 Ranbaxy Laboratories Limited 3,6-disubstituted azabicyclo [3.1.0] hexane derivatives as muscarinic receptor antagonists
WO2004078749A1 (en) * 2003-03-06 2004-09-16 Glaxo Group Limited Heterocyclic urea derivatives for the treatment of pain
WO2005051390A1 (en) * 2003-10-29 2005-06-09 Merck Sharp & Dohme Limited E-fluoro-4-(pyridin-2-yl)-piperidine-1-carboxamide derivatives and related compounds which modulate the function of the vanilloid-1 receptor (vr1) for the treatment of pain
WO2007029086A2 (en) * 2005-09-05 2007-03-15 Ranbaxy Laboratories Limited Derivatives of 3-azabicyclo[3.1.0]hexane as dipeptidyl peptidase-iv inhibitors
WO2007077508A2 (en) * 2005-12-30 2007-07-12 Ranbaxy Laboratories Limited Derivatives of beta-amino acid as dipeptidyl peptidase-iv inhibitors

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993018001A1 (en) * 1992-03-02 1993-09-16 Pfizer Inc. Preparation of intermediates in the synthesis of quinoline antibiotics
US5475116A (en) * 1994-04-29 1995-12-12 Pfizer Inc. Aza bicyclo[3,1,0]hexane intermediates useful in the synthesis of quinolones
US6194438B1 (en) * 1998-12-02 2001-02-27 Pfizer Inc. Derivatives of 2-(2-oxo-ethylidene)-imidazolidin-4-one, and compositions and methods for inhibiting abnormal cell growth comprising said derivatives
US6184380B1 (en) * 1999-01-25 2001-02-06 Pfizer Inc. Process for preparing naphthyridones and intermediates
WO2002090326A1 (en) * 2001-05-02 2002-11-14 Smithkline Beecham P.L.C. Heterocyclic ureas, their preparation and their use as vanilloid receptor antagonists
WO2004052857A1 (en) * 2002-12-10 2004-06-24 Ranbaxy Laboratories Limited 3,6-disubstituted azabicyclo [3.1.0] hexane derivatives as muscarinic receptor antagonists
WO2004078749A1 (en) * 2003-03-06 2004-09-16 Glaxo Group Limited Heterocyclic urea derivatives for the treatment of pain
WO2005051390A1 (en) * 2003-10-29 2005-06-09 Merck Sharp & Dohme Limited E-fluoro-4-(pyridin-2-yl)-piperidine-1-carboxamide derivatives and related compounds which modulate the function of the vanilloid-1 receptor (vr1) for the treatment of pain
WO2007029086A2 (en) * 2005-09-05 2007-03-15 Ranbaxy Laboratories Limited Derivatives of 3-azabicyclo[3.1.0]hexane as dipeptidyl peptidase-iv inhibitors
WO2007077508A2 (en) * 2005-12-30 2007-07-12 Ranbaxy Laboratories Limited Derivatives of beta-amino acid as dipeptidyl peptidase-iv inhibitors

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
CHEM. EUROP. J., vol. 8, no. 16, 2002, pages 3789 - 3801 *
DATABASE BEILSTEIN BEILSTEIN INSTITUTE FOR ORGANIC CHEMISTRY, FRANKFURT-MAIN, DE; XP002465472, Database accession no. BRN:8563110 *
DATABASE BEILSTEIN BEILSTEIN INSTITUTE FOR ORGANIC CHEMISTRY, FRANKFURT-MAIN, DE; XP002465473, Database accession no. BRN:9222926 *
ELMAR VILSMAIER ET AL: "Reductive decyanation of N-protected 6-Amino-3-azabicyclo(3.1.0)hexan ecarbonitriles", TETRAHEDRON, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 54, no. 23, 1998, pages 6403 - 6414, XP002081309, ISSN: 0040-4020 *
GILLASPY M L ET AL: "A Simple Method for the Formation of Cyclopropylamines: The First Synthesis of Tricyclopropylamine", TETRAHEDRON LETTERS, ELSEVIER, AMSTERDAM, NL, vol. 36, no. 41, 9 October 1995 (1995-10-09), pages 7399 - 7402, XP004027008, ISSN: 0040-4039 *
J. CHEM. SOC. PERKIN TRANS., vol. 10, 2000, pages 1615 - 1622 *

Also Published As

Publication number Publication date
AR061905A1 (en) 2008-10-01
WO2008010061A2 (en) 2008-01-24

Similar Documents

Publication Publication Date Title
WO2008010061A3 (en) 3-azabicyclo [3.1.0] hexane vanilloid receptor ligands, pharmaceutical compositions containing them, and processes for their preparation
WO2009090548A3 (en) 3-azabicyclo [3.1.0] hexane derivatives as vanilloid receptor ligands
TW200801013A (en) Substituted benzofused derivatives and their use as vanilloid receptor ligands
MY159059A (en) 2-amino-4-arylthiazole compounds as trpa1 antagonists
WO2008152099A3 (en) Aryl/hetarylamides as modulators of the ep2 receptor
WO2010048332A3 (en) Compounds for treating ophthalmic diseases and disorders
WO2007052023A3 (en) Novel compounds
WO2009111700A3 (en) Oxadiazoanthracene compounds for the treatment of diabetes
WO2012009009A3 (en) Novel 2-amino-4-pyrazolyl-thiazole derivatives and their use as allosteric modulators of metabotropic glutamate receptors
WO2008152093A3 (en) Diaminopyrimidines as modulators of the ep2 receptor
WO2010008831A3 (en) Compounds and methods for modulating g protein-coupled receptors
WO2008059339A3 (en) Isoquinoline derivatives as vanilloid receptor modulators
WO2008132139A3 (en) New heterocyclic derivatives useful for the treatment of cns disorders
WO2007079163A3 (en) Prokineticin 1 receptor antagonists
WO2006067428A3 (en) 1, 2-diphenyl-imidazole derivatives and their use as cb1 receptor ligands
WO2008153937A3 (en) Novel 1- heteroaryl-3-azabicyclo[3.1.0]hexanes, methods for their preparation and their use as medicaments
WO2008005908A3 (en) Pyridoimidazole derivatives
WO2009104021A3 (en) Novel polymorphs and processes for their preparation
WO2007041076A3 (en) 1,2,3,5-tetrahydro-cyclopental[c]quinolin-4-one derivatives as rxr agonists for the treatment of dyslipidemia, hypercholesterolemia and diabetes
WO2006077024A3 (en) 5-aminoindole derivatives
WO2010054024A3 (en) 1, 2 -thiazol yl derivatives as cannabinoid receptor ligands
WO2011132051A3 (en) Tricycle compounds as phosphodiesterase-10 inhibitors
WO2009038385A3 (en) Novel compounds having indazole frameworks, methods for preparing the same and pharmaceutical composition comprising the same
WO2010010435A3 (en) Fused oxazole and thiazole derivatives as trpms modulators
WO2009084034A3 (en) Chromane derivatives as trpv3 modulators

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07804611

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 07804611

Country of ref document: EP

Kind code of ref document: A2